We conducted a trial of oral acetazolamide for the treatment of cryptococcal meningitis in 22 Thai adults with headache and an opening cerebrospinal fluid pressure of у200 mm H 2 0. The trial was terminated prematurely because patients who received acetazolamide developed significantly lower venous bicarbonate levels and higher chloride levels and had more-frequent serious adverse events than did subjects who received placebo.
ports suggest that orally administered acetazolamide, which is inexpensive and readily available, may be beneficial in reducing intracranial pressure in patients with cryptococcal meningitis [4] [5] [6] 8] . Acetazolamide can cause hypokalemia and metabolic acidosis, especially in patients with renal impairment [9] ; these adverse effects may also be caused by amphotericin B-the drug of choice for cryptococcal meningitis. However, acetazolamide is well tolerated when used in the treatment of glaucoma and "benign" intracranial hypertension and as prophylaxis against acute mountain sickness. We conducted a randomized, double-blind, placebo-controlled trial of oral acetazolamide in amphotericin-treated patients with cryptococcal meningitis, elevated intracranial pressure, and headache to test whether acetazolamide would reduce intracranial pressure and alleviate headache without causing severe acidosis and hypokalemia.
Methods. The study was performed from 1998 through 2000 in Ubon Ratchatani and Khon Kaen, which are located in northeast Thailand. Patients aged у16 years were included if they or attending relatives provided written informed consent and if the following criteria were present: cryptococcal meningitis with yeasts demonstrated on an India ink preparation of CSF specimens obtained at admission to the hospital, a CSF opening pressure of у200 mm H 2 0 noted from lumbar puncture performed at admission, headache, a Glasgow Coma Score of у11, normal serum electrolyte and creatinine levels at admission, and weight of у35 kg. Patients were excluded if they were pregnant or breast-feeding or if they had known hypersensitivity to sulfonamides, contraindications for acetazolamide therapy, a systolic blood pressure of !100 mm Hg, a known intracerebral lesion, or an infection other than cryptococcosis and HIV infection. No patient received antiretroviral therapy, CD4 lymphocyte counts could not be determined, and cerebral CT scanning was not performed.
Lumbar puncture was performed using 18-G spinal needles, and CSF opening pressures were recorded using disposable manometers. All patients received standard dosages of amphotericin B (1 mg/kg per day [Fungizone; Squibb]). Patients were randomized in groups of 10 to receive either oral acetazolamide (250 mg per tablet [Glaupax; Ercopharm]) or an identicalappearing placebo that was made of lactose, starch, and magnesium stearate. For patients who weighed 145 kg, the starting dosage was 1 tablet given every 6 h. The dose interval was reduced according to serum creatinine level, as follows: the interval was reduced to 12 h for patients with a serum creatinine level of 186-266 mM and to 24 h for those with a serum cre-atinine level of 267-354 mM; no tablets were given to patients whose level increased to 1354 mM. For patients who weighed 35-45 kg, the starting dosage was 1 tablet given every 8 h; the dose interval was reduced to 24 h for patients with a serum creatinine level of 186-266 mM, and no tablets were given to patients whose level increased to 1266 mM. Oral potassium supplements were given if the patient's serum potassium level decreased to !3.0 mM, and bicarbonate supplements were provided if the venous bicarbonate level decreased to !15 mM.
The primary outcome measures were CSF opening pressure, headache severity, and serum potassium and bicarbonate levels. We aimed to include 60 patients in the trial, because this allowed a difference in the proportion of patients with pressures remaining 1200 mm H 2 0 at 14 days of 80% and 40% to be detected with 95% confidence and 80% power, as well as a 10% drop-out rate. An interim analysis was planned after 30 patients were enrolled. Pulse, blood pressure, respiratory rate, Glasgow Coma Score, Headache Visual Analogue Score, and Karnofsky score were recorded every morning. The Headache Visual Analogue Score was determined by showing the patient a 12-inch ruler and asking him/her to assign a number to rate the headache, with 0 representing no headache and 12 representing the worst headache that the patient could imagine. Lumbar punctures were repeated on the second, fourth, seventh, and 14th day after commencement of the acetazolamide/ placebo regimen (and on other days at the discretion of the responsible physician); CSF opening and closing pressures and the volume of CSF removed were measured. Before each lumbar puncture was performed, the levels of serum electrolytes, bicarbonate, creatinine, and urea were measured. CSF yeast cell counts on India ink, WBC count, protein level, and glucose level were measured.
Statistical analysis was performed with SPSS, version 9.0 (SPSS), using nonparametric tests (Mann-Whitney U test and Spearman rank correlation test). The study was approved by the Ethical and Scientific Review Committee of the Ministry of Public Health, Royal Government of Thailand (Bangkok).
Results. Twenty-four patients (10 in Ubon Ratchatani and 14 in Khon Kaen) were enrolled the study. Two patients were withdrawn from the study because they were found to be underweight (both received acetazolamide, which was stopped after 1 day in 1 patient who did not have adverse effects and after 6 days in 1 patient who became acidotic and who was taken home against medical advice). Because a high prevalence of severe acidosis was encountered, the data were reviewed by an external monitor after 24 patients had been recruited; he advised termination of the study.
The enrolled patients were well matched by the randomization (table 1). All patients but 1, for whom no cause of immunodeficiency could be found, were HIV infected. Amphotericin B therapy was continued until discharge from the hospital or for a maximum of 14 days. The median daily doses of acetazolamide were 20.4 mg/kg (range, 15.4-22.7 mg/kg) and 17.5 mg/kg (range, 12.5-20.6 mg/kg) on the first and 14th day, respectively ( ). All patients received acetamino-P p .11 phen, 6 received nonsteroidal or opiate analgesics, 19 received oral potassium supplements, 5 received metoclopramide, 5 received sodium bicarbonate, and 1 received intravenous and intraocular dexamethasone for the management of visual loss.
Intracranial pressure did not decrease and the Karnofsky score did not improve between study admission and day 14 of treatment in either group or for all patients combined (
; figure 1, table 1 ). The headache score improved sig-P 1 .2 nificantly over the course of the 14 days ( ), but there P p .002 was no significant difference between the 2 treatment groups.
Five patients (all of whom were in the acetazolamide treatment arm) developed serious adverse events, defined as events attributable to the drug that caused significant morbidity, risk of death, or death itself. Two patients died: one died on day 13 after having visual loss, and the other died on day 7 after developing acidosis, acidotic breathing, and coma. In addition, 1 patient developed visual loss, 1 developed a peripheral sensory neuropathy, and 1 developed severe symptomatic acidosis with acidotic breathing, despite attempted correction. The median serum bicarbonate levels for these 5 patients on the day that the first severe adverse event was recorded ‫1ע(‬ day) was 13.1 mM (range, 6.5-16.0 mM).
Patients in the acetazolamide group consistently developed a severe hyperchloremic acidosis, which was apparent by day 2 (median serum bicarbonate levels in the placebo and acetazolamide groups, 18.7 mM and 16.1 mM, respectively; P p ). The serum bicarbonate level was significantly lower in .024 the acetazolamide group than it was in the placebo group on days 4, 7, and 10 (data not shown), as well as on day 14. Nine (41%) of 22 patients (7 patients [78%] in the acetazolamide group and 2 [22%] in the placebo group) had a serum bicarbonate level of р15 mM on у1 day. In 6 of the 9 cases, the acidosis appeared to be asymptomatic, but the symptoms could have been clinically masked by meningitis and HIV infection. There was a positive linear correlation between serum bicarbonate level and serum potassium level ( ; ) 2 P p .002 R p 0.4 on day 4, but not on subsequent days ( ). P 1 .1 Twelve patients were evaluable on day 14. The shorter duration of hospital stay in the acetazolamide group was a result of death and of patients being taken home by relatives who believed that the patients' conditions were not improving. There was no significant relationship between the change in CSF opening pressure and the change in serum bicarbonate level from the day of admission to day 14.
Discussion. This evaluation of acetazolamide for the treatment of elevated intracranial pressure complicating cryptococcal meningitis was terminated prematurely, because indepen- dent review strongly suggested that acetazolamide therapy was harmful, with an excess of severe acidosis and adverse events. This study has insufficient power to characterize the effect, if any, of acetazolamide on intracranial pressure, headache, or Karnofsky score. The severity of the acidosis, combined with hypokalemia, suggests that acetazolamide has an additive or synergistic toxicity with amphotericin B resulting from renal tubular dysfunction.
The antisecretory effects of acetazolamide may be insufficient to reduce intracranial pressure in the face of severe outflow obstruction (caused by cryptococci or capsular polysaccharide) of CSF drainage through the arachnoid villi [2] . Acetazolamide should not be used in combination with amphotericin B for the treatment of cryptococcal meningitis. This study does not address whether acetazolamide may be beneficial for patients receiving lipid formulations of amphotericin B; for HIV-negative patients; for the palliation of symptoms of elevated intracranial pressure, if used in areas where amphotericin B is not affordable [10] ; or after the amphotericin B course has finished.
Cryptococcal meningitis remains a serious, common HIVassociated infection in tropical regions. There is urgent need for clinical trials to test whether interventions, such as frequent lumbar punctures with large-bore needles, placement of lumbar drains, or steroid therapy, are beneficial for the treatment of elevated intracranial pressure associated with cryptococcal meningitis.
